Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000541847 | SCV000629286 | likely benign | Retinoblastoma | 2024-12-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002395310 | SCV002702402 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-05-26 | criteria provided, single submitter | clinical testing | The p.T502I variant (also known as c.1505C>T), located in coding exon 17 of the RB1 gene, results from a C to T substitution at nucleotide position 1505. The threonine at codon 502 is replaced by isoleucine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
All of Us Research Program, |
RCV000541847 | SCV004844677 | uncertain significance | Retinoblastoma | 2024-02-05 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with isoleucine at codon 502 of the RB1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with breast cancer in the literature (PMID: 28202063). This variant has been identified in 1/241956 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Gene |
RCV004592554 | SCV005081130 | uncertain significance | not provided | 2023-12-04 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Observed in individuals with breast or other cancer history and has not been reported in individuals with RB1-related cancers to our knowledge (PMID: 35534704, 28202063); This variant is associated with the following publications: (PMID: 28202063, 35534704, 23516486, 31980996) |